Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analysesHongchao Pan, Ligita Jančorienė, Richárd Pető et al.|The Lancet|2022Cited by 407
The effects of different types of organisational workplace mental health interventions on mental health and wellbeing in healthcare workers: a systematic reviewBirgit Aust, Kahar Abdulla, Caleb Leduc et al.|International Archives of Occupational and Environmental Health|2024Cited by 50
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, Alpha Diallo, Michael Joannidis et al.|Critical Care|2023Cited by 47
Supporting employees with mental illness and reducing mental illness-related stigma in the workplace: an expert surveyBridget Hogg, Lars de Winter, Ana Moreno‐Alcázar et al.|European Archives of Psychiatry and Clinical Neuroscience|2022Cited by 42
Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 TrialMarius Trøseid, Alpha Diallo, José Ramón Arribas et al.|SSRN Electronic Journal|2022Cited by 1